Drug Search Results
More Filters [+]

Imagabalin

Alternative Names: imagabalin, pd-0332334, pd0332334, pd 0332334
Latest Update: 2019-08-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Voltage-Gated Calcium Channel Binder

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Imagabalin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Generalized anxiety disorder|Depressive Disorder|Pregnancy Outcomes

Phase 2: Generalized anxiety disorder

Phase 1: Healthy Volunteers|Generalized anxiety disorder|Kidney Diseases|Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-004443-11

P3

Terminated

Generalized anxiety disorder

2012-01-03

2008-000761-32

P3

Terminated

Generalized anxiety disorder

2010-02-25

ND

P3

Terminated

Generalized anxiety disorder

2010-01-09

2008-000763-42

P3

Terminated

Generalized anxiety disorder

2009-09-25

Recent News Events

Date

Type

Title